Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2016 · 18 citations · 23 references
Life SciencesMolecular BiologyOncologyApoptosisMolecular OncologyTumor ProgressionApoptosis In CancerLung CancerMalignant NeoplasmsMicrorna BiologyMicrorna-mediated RegulationRna InterferenceMicrorna Function In CancerMicrorna In ApoptosisMicrorna In CancerMicrorna In Cell ProliferationMicrorna ModulationMicrorna Regulation In CancerMicrorna Regulation Of ApoptosisMicrorna Regulation Of Senescence
The ribosomal protein (RP)-p53 pathway has been shown to play a key role in apoptosis and senescence of cancer cells. miR-1908 is a newly found miRNA that was reported to have prognostic potential in melanoma. However, its role and mechanism in the progression of non-small cell lung cancer (NSCLC) are largely unknown. In this study, we found that expression of miR-1908 was significantly downregulated in human NSCLC cell lines, including SK-MES-1, A549, and NCI-H460. Then the role of miR-1908 in NSCLC cell proliferation was explored. The miR-1908 mimic was transfected into NSCLC cell lines, and their proliferation was detected. MTT and Cell Titer-Blue H analyses showed that the cell proliferation was notably reduced by the miR-1908 mimic transfection. Moreover, we found the RP-p53 pathway was activated by miR-1908 mimic. Moreover, the miR-1908 inhibitor transfection had a completely opposite effect on the NSCLC cell proliferation than that of miR-1908 mimic. To explore the underlying mechanism of that, TargetScan bioinformatics server and 3'-UTR luciferase reporter assay were applied to identify the targets of miR-1908. Our results showed that AKT1 substrate 1 (AKT1S1), a newly proven suppressor of the RP-p53 pathway, was a target of miR-1908, suggesting a probable mechanism for miR-191 suppressing NSCLC cell proliferation. Our findings provide a novel molecular target for the regulation of NSCLC cell proliferation.
23
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Targeting PI3K/Akt/mTOR Signaling in Cancer
Camillo Porta, Chiara Paglino, Alessandra Mosca · Frontiers in Oncology · 2014 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +15
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Emilie Vander Haar, Seong-il Lee, Sricharan Bandhakavi et al. · Nature Cell Biology · 2007 · 1.2K citations
Targeting PI3K/mTOR Signaling in Cancer
Frontiers in Oncology · 2014 · 1K citations · Full text
Medicine, Cancer Biology, Oncology +17
Elsevier eBooks · 2016 · 859 citations
Medicine, Oncology, Oncology Nursing +15